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Background: The availability of medicines in public health facilities in Tanzania is problematic. Medicines shortages
are often caused by unavailability at Medical Stores Department, the national supplier for public health facilities.
During such stock-outs, districts may purchase from private suppliers. However, this procedure is intransparent,
bureaucratic and uneconomic.
Objectives: To complement the national supply chain in case of stock-outs with a simplified, transparent and
efficient procurement procedure based on a public-private partnership approach with a prime vendor at the
regional level. To develop a successful pilot of a Prime Vendor system with the potential for national scale-up.
Methods: A public-private partnership was established engaging one private sector pharmaceutical supplier as the
Prime Vendor to provide the complementary medicines needed by public health facilities in Tanzania. The Dodoma
pilot region endorsed the concept involving the private sector, and procedures to procure complementary supplies
from a single vendor in a pooled regional contract were developed. A supplier was tendered and contracted based
on Good Procurement Practice. Pilot implementation was guided by Standard Operating Procedures, and closely
monitored with performance indicators. A 12-step approach for national implementation was applied including
cascade training from national to facility level. Each selected vendor signed a contract with the respective regional
authority.
Results: In the pilot region, tracer medicines availability increased from 69% in 2014 to 94% in 2018. Prime vendor
supplies are of assured quality and average prices are comparable to prices of Medical Stores Department.
Procurement procedures are simplified, shortened, standardized, transparent and well-governed. Procurement capacity
was enhanced at all levels of the health system. Proven successful, the Prime Vendor system pilot was rolled-out
nationally, on government request, to all 26 regions of mainland Tanzania, covering 185 councils and 5381 health
facilities.
Conclusion: The Prime Vendor system complements regular government supply through a regional contract
approach. It is anchored in the structures of the regional health administration and in the decentralisation policy of the
country. This partnership with the private sector facilitates procurement of additional supplies within a culture of
transparency and accountability. Regional leadership, convincing pilot results and policy dialogue have led to national
roll-out. Transferring this smaller-scale supply chain intervention to other regions requires country ownership and
support for sustainable operations.
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Access to health care is determined by availability of
medicines and medical supplies [1]. Availability of qual-
ity medicines in the provision of health care service is an
integral part of universal health coverage (UHC) [2].
Medicines are essential for health care service delivery
[3, 4] and account for a high proportion of the health
care budget and of household expenditure [5]. Limited
availability of medicines is a common feature in most of
the public health facilities in developing countries [2, 6,
7]. Clinicians depend on effective, safe and good quality
medicines to provide adequate health care, and patients
equate quality of care with the availability of medicines.
Furthermore, availability of medicines affects patient trust
to the health care providers [8]. Evidence has shown that
shortage of medicines influences health care seeking
behaviour [9, 10]. If out of stock, patients suffer and lose
confidence in health services. Stock-outs in health facil-
ities discourage people from enrolling into health insur-
ance schemes and shape their decisions for membership
renewal in the case of enrolled individuals [11, 12].
A range of actors, processes, and information is
needed to get health products to people along a supply
chain and throughout the complex health care system.
Various players must collaborate to ensure effective, reli-
able, and flexible supply chains that provide equitable
access to health services for all people. The private sec-
tor can play an important role in strengthening supply
chains for health by creating synergies [13]. These
public-private partnerships (PPP) however must be
based on policy and a mutual understanding of the
duties and benefits for both partners, tailoring collabor-
ation to the socioeconomic and political context, and
local environments [14–16]. One example is the Prime
Vendor (PV) approach where the government relies on a
private sector firm to manage the supply of a line of
products, and provides services to customers in an
assigned area of responsibility. Diverse setups of vendor
supply systems are possible to obtain medical supplies for
public health facilities from private sector suppliers [17].
Medical Stores Department (MSD) is the backbone for
public supply of medicines and other health commodities
in Tanzania. But the organisation faces challenges in filling
orders of health facilities leading to stock-outs at service
delivery points. An increase in demand for health care
services and expanding coverage of interventions, delays
in disbursement of funding for health commodities, an in-
adequate governance framework, management challenges
such as shortage of staff and operational inefficiencies
have resulted in working capital erosion at MSD with an
unsustainable level of debt accumulating [18, 19].
Centrally, the Ministry of Health, Community Devel-
opment, Gender, Elderly and Children (MoHCDGEC)
allocates defined sums for medical supplies for eachpublic health facility directly to MSD. Health facilities
have three main sources of funding for their supplies:
direct funding deposited at MSD by the government,
health basket funds1 and complementary funds collected
by the health facility. These include funds from the com-
munity health fund (CHF)2, national health insurance,
and cost-sharing (user fees). Health facilities dedicate up
to 67 % of these complementary funds to the purchase
of medicines and health commodities, when not avail-
able at MSD.Problem statement
A review of the national supply chain in Tanzania in 2013
revealed that despite some gains made by vertical pro-
grams, general essential medicines availability remained
insufficient, resulting in frequent stock-outs of medicines
at health service delivery points [18]. Similarly, in Dodoma
region, a comprehensive baseline survey in 2011 revealed
an availability of essential medicines of 53% with a corre-
sponding stock-out rate of 47%, based on 24 tracer medi-
cines (unpublished: Swiss TPH. HPSS project, internal
report. 2013). The order fulfilment rate by Medical Stores
Department was 58.6%.
The supply gap of more than 40% stemming from the
out-of-stock situation and low order fulfilment rates for
supplies by MSD needs to be complemented through
other sources. Previously, health facilities filled this gap
with purchases by quotation and using complementary
funds and health basket funds from multiple private
sources, within and outside Dodoma region, incurring
high opportunity costs (travel and fuel, per diems, high
prices of medicines) in the process and making the
whole task of filling this gap cost inefficient. The proced-
ure was uneconomic, bureaucratic, non-transparent, and
lengthy, while supplies were of questionable quality.
Alternative strategies were needed to fill the supply gap
and to complement the public sector supply system.Approach
To resolve this situation, the Dodoma Regional Admin-
istration and Local Government (RALG) embarked on a
novel process to establish a Prime Vendor system and to
engage, on a public-private partnership (PPP) basis [20],
one private sector pharmaceutical vendor as the primary
supplier for supplementary medicines and medical sup-
plies needed by public health facilities in the region.
In principle, a Prime Vendor system (PVS) was estab-
lished in Dodoma region serving as a “one stop shop”
which was intended to alleviate opportunity costs previ-
ously incurred by health facilities when searching for
alternative sources of supplies which they could not ob-
tain from MSD. At health facility level, the complemen-
tary funds formerly used to purchase from multiple
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only one appointed Prime Vendor (PV).
This paper summarizes the implementation results of
the PVS pilot in Dodoma region, Tanzania, and outlines
its evolution from a promising concept to a successful
pilot, finally culminating in a nationwide scale-up and
rollout of this policy-supported national supply chain
solution.
Methods
Concept and pilot
In 2012, a concept note, backed by existing laws, policies
and guidelines, was widely circulated and discussed
among stakeholders in Dodoma region. Councils and
the region endorsed a PV concept involving the private
sector. This was realised following a regional stake-
holders meeting which explored various options for fill-
ing the supply gap arising from MSD challenges of
meeting health facility needs. After detailed analysis of
advantages and disadvantages of various options, the
meeting adopted a PPP approach based on a pooled
regional contract with one vendor but with individual
orders by districts from the contracted vendor only. The
methodology for implementation of the PV concept
followed a sequence of general steps as presented in Table 1.
Regional authorities carried out a transparent prequali-
fication and procurement process to select and contract
a private supplier acting as the regional PV, based on
Good Procurement Practice (GPP). Requirements for a
PV were spelled out in detail in the prequalification
and tender documents. Criteria included legal status,Table 1 General steps for implementation
Step No Objective Expected output
1 Baseline data Quantification of medicines
Current private procuremen
Financial management of co
2 Advocacy and buy-in Consent and buy-in is reach
3 Administrative structures A PV technical committee, P
with TORs
A Jazia PVS office is identifie
A Jazia PVS coordinator is ap
4 Jazia PVS documents All documents driving the Ja
5 Vendor Forum Interested private suppliers a
6 Prequalification A selected number of poten
7 Tender A final supplier (Prime Vend
8 PPP contracting PPP contract is negotiated b
9 SOP and M&E documents SOPs and a M&E framework
10 Launch The Jazia PVS is officially lau
supplier
11 PVS training Regional and district stakeho
Operations start
12 Follow-up Backstopping, M&E and med
PVS are assessed and regionlitigation history, general capacity and in particular supply
experience of medical commodities, financial position,
personnel and equipment capabilities and other relevant
information. Tenderers had to satisfy all relevant licensing
and/or registration and tax requirements, submit a Con-
flict of Interest declaration and tender prices. These re-
quirements are based on the national Public Procurement
Act [21]. Prices from the contracted PV were fixed and
comparable to MSD catalogue prices. To assure efficacy,
safety and quality in accordance with MoHCDGEC and
Tanzania Food and Drug Authority (TFDA) standards, PV
supplies had to be limited to and comply with the national
essential medicines list, be registered and approved.
A regional PVS office was established within the re-
gional administration, represented by a PV coordinator,
a dedicated pharmacist and support staff. Mandated ad-
ministrative structures such as a Technical Committee
and a Board were appointed by the regional authorities
to closely manage and support the PVS.
Standard Operating Procedures (SOPs) were elabo-
rated to manage and drive operations of the PVS. A
comprehensive but user-friendly handbook with SOPs
for health facilities and councils was developed, covering
six key operational areas as listed in Table 2:
All stakeholders involved in the PVS were trained in
the use of SOPs.
A monitoring and evaluation (M&E) handbook was
developed describing the framework for monitoring
and evaluating the performance of both the system and
the PV. This included instructions on monitoring
responsibility and frequency, and performance metrics.needs is available
t practices are analysed
mplementary funds, flow, amount and procedures is assessed
ed by all stakeholders
V board and temporary tender evaluation committee is appointed
d, equipped and staffed
pointed and instructed
zia PVS are reviewed and approved
re informed a possible PPP and have prequalification documents
tial suppliers have been prequalified
or) is selected and approved
etween the regional authority and the private supplier
is available and approved
nched by signing the contract between regional authority and private
lders and health facility staff are competent in SOP of Jazia PVS activities
icines and financial audits are conducted. Enablers and obstacles of Jazia
al team is supported
Table 2 Standard Operating Procedures
SOP # Prime Vendor Operational Area Level
1 Determination of quarterly
order quantities to be purchased
from PV by health facility
Health facility
2 Health facility orders consolidation
and forwarding to PV
District headquarter
3 Receiving and inspection
of consignments from PV
District headquarter
4 Inspection of supplies from PV Health facility
5 Funds transfer & payment to PV Health facility
6 Lines of communication
within PV system
Health facility - district-
regional PV office - PV
Wiedenmayer et al. Journal of Pharmaceutical Policy and Practice            (2019) 12:4 Page 4 of 10The responsibility of semi-annual monitoring was given
to the PV coordination office, a regional instance.
Sources of data used were the baseline survey and
M&E reports. Key supply chain indicators were defined
to measure system performance of the PVS model.
They include medicines availability based on 24 tracer
medicines, PV utilization, delivery lead time to health
facility, promptness of payment to PV by district and
satisfaction of councils with PV services. Additional
indicators to monitor the performance of the PV as a
supplier were formulated; they cover physical product
quality, order fulfilment rate, delivery lead time and
general quality of communication regarding PV ser-
vices. Regional and district stakeholders and health care
workers at facility level were oriented and trained on
Jazia PVS activities, with a focus on SOPs and M&E
procedures.
In September 2014, the pilot PVS was launched in the
presence of the Deputy Minister of Health and regional
and local government authorities of Dodoma. Subse-
quently, the PV system was formally registered with the
Business Registration and Licensing Agency in Tanzania
as Jazia PVS.
The PV concept entailed designing an operational
system. Figure 1 below illustrates the fully functional
Jazia PVS and the synergy created by the collabor-
ation between MSD and the PVS in improving
medicines availability at public health facilities in
Dodoma region.Accompanying measures and interventions
In addition to the Jazia PVS, a bundle of systemic supply
chain interventions was introduced to improve account-
ability, medicines availability and access to therapy for
patients. These include capacity building, peer coaching
and auditing. In addition, public financial management
was reviewed and revised to standardize and simplify
procedures and transactions.Scaling up for national roll-out
Following the successful implementation in Dodoma
region, the Jazia PVS was expanded to two more regions
(Morogoro and Shinyanga) in 2016. This was also stipu-
lated in one of the strategic directions in the Tanzanian
Health Sector Strategic Plan IV [22]. In 2017, the
Tanzanian government through the President’s Office -
Regional Administration and Local Government
(PORALG) and the Ministry of Health (MoHCDGEC)
requested the national roll-out of the Jazia PV system in
all 26 regions of mainland Tanzania. This entailed
scaling up to 23 additional regions in Tanzania. The
PORALG was able to access co-funding from develop-
ment partners through the health basket fund. They
were integrated in the preparation of the national
roll-out plan and participated in the capacity building
during cascade training.
A national Coordination Committee was formed, com-
posed of members from ministries and agencies. A task
force reviewed documents guiding the establishment of
Jazia PVS for adoption. The task included development
of a training manual, reviewing Terms of Reference
(TOR) for structures supporting the establishment of
Jazia PVS and adaptation of tender documents in
accordance with the Public Procurement Act guided by
the Public Procurement Regulatory Authority.
A comprehensive package of documents including
guidelines, TOR, templates and training material was
prepared and logistics planned. In principle, the 12-step
approach for implementation (see Table 1) was applied.
Training on the Jazia PVS was conducted in a cascaded
and stepwise manner. A master training at national level
instructing 36 master trainers was followed by training for
regional trainers at zonal level. Regional trainers con-
ducted training of district teams in the respective regions.
National master trainers were responsible for coordinating
and supporting regions to ensure agreed standards. The
cascade roll-out ended with the training of health care
workers at health facility level. Concurrently, a national
Vendor Forum started the tender process. Prequalification
of potential vendors and subsequent tendering took place.
Each selected vendor (PV) signed a contract with the
respective regional authority. After a national launch in
October 2018, operations based on the model Jazia PVS of
Dodoma region started.
Results
The establishment of the Jazia PVS fostered an environ-
ment of robust and transparent procurement practice,
through an innovative public-private partnership. Now,
when MSD notifies stock out of items, councils procure
complementary medicines individually, using the PV
under regional contract, which allows them to benefit
from economies of scale. Health facilities manage their
Fig. 1 Concept of the fully functioning Jazia Prime Vendor System
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autonomy. Facility funds are used for pooled purchase
from the PV, based on the PPP framework contract.
Transparency and accountability in procurement proce-
dures is assured as the PV tender process adheres to the
Public Procurement Act. Corruption risks are managed
by detailed and strict procurement rules as defined by the
Public Procurement Act, a Conflict of Interest declaration,
a risk mitigation plan and due diligence procedures.SOPs guide the process and the purchase of medi-
cines from the PV when these are either out of
stock, in short supply or not stocked by MSD. All
orders from health facilities are consolidated at the
district level and forwarded to the PV. System per-
formance is monitored on semi-annual basis using
supply chain metrics defined in a comprehensive
M&E framework. Monitoring is conducted by the PV
coordination office.
Table 3 Key performance indicators for Jazia PVS
Indicator for PV System performance Baseline October 2014 July 2015 July 2016 July 2017 July 2018 Target
Mean availability of tracer medicines (%) 69 75 83 81.5 94 100
PV utilization by health facilities by value of orders (%) N/A 47 53 50 53 as required
Delivery time from district HQ to health facility (days) N/A 1–20 14–60 < 5 < 8 < 14
Promptness of payment to PV by district (days) N/A 14–30 22–300 3–117 12–90 < 22
Councils satisfaction with PV services (score) N/A 20 17 18 19 20
Indicator for PV (supplier) performance Target as per PV contract
Overall physical product quality (score) N/A 20 19 20 20 20
Order fulfillment rate (score) N/A 20 25 23 25 25
Delivery lead time from PV to district HQ (score) N/A 14 13 15 15 15
General quality of communication (score) N/A 5 3 4 5 5
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relating the latest monitoring metrics to contractual
targets.
Tracer medicines availability in the region (mean avail-
ability of all districts) increased from 69% in 2014 to
94% in 2018 (Fig. 2). All councils and 31% of health fa-
cilities placed orders to the PV by July 2018. Delivery of
health commodities from district HQ to the health
facilities was done within the contractual delay of 14
days. Satisfaction of councils and health facilities with
the PV performance as a complementary supplier wasFig. 2 Tracer medicines availability in % (2013–2018), Dodoma regiongood, as was the overall physical quality of health
supplies. Order fulfilment rate of the contracted PV was
99% reaching the maximum score. The PV adhered to
and generally significantly beat the contractual delivery
time of 22 days with recorded delivery lead times of be-
tween 4 and 15 days. General quality of communication
and client responsiveness was recorded as good, with
no complaints noted. Payment by the districts for their
PV consignments however varied among districts and
has seen delays of up to 90 days, not adhering to con-
tractual terms.
Wiedenmayer et al. Journal of Pharmaceutical Policy and Practice            (2019) 12:4 Page 7 of 10In 2018 the Jazia PVS was rolled out from the initial
three pilot project regions to an additional 23 regions,
thus covering all 26 regions of mainland Tanzania, in-
cluding 185 councils, 5381 Health facilities and a total
population of 51,400,000. The roll-out exercise itself
enhanced capacity in procurement procedures and Good
Procurement Practice at all levels of the health system
in both the public and private sector. The scaling up of
the Jazia PVS to all regions of mainland Tanzania being
recent, results on key performance indicators are not
yet available. Monitoring and close follow-up of metrics
will be critical.Discussion
The procurement procedure for complementary health
supplies when MSD notifies stock-outs was simplified
and orders are now coordinated in a standardized and
well-governed system approach. The Jazia PVS has re-
placed a lengthy, bureaucratic and intransparent procure-
ment practice with an efficient, formalized, transparent
and innovative PPP model. Monitoring of performance
indicators has shown important improvement in the sup-
ply chain. Mean availability of medicines at health facilities
in the pilot region of Dodoma increased by over 35%
between 2014 and 2018.
Client responsiveness and the contractual business
relationship of the PPP have contributed to this result.
Delivery time for complementary supplies is short and
order fulfilment rate is high. Only 31% of health facilities
placed orders to the PV during the last semi-annual
monitoring period. This may indicate stock sufficiency
but it could also mean that some facilities are not yet
sufficiently familiar with the procedures of the comple-
mentary supply system.
A PPP is based on a mutual understanding of the du-
ties and benefits for both partners. In the pilot region,
several districts initially delayed payment to the PV. This
was due to weak financial management and to resistance
to a transparent new supply system. Mitigating measures
were simplification of financial transfers, continued
persuasion of all actors regarding the successful inter-
vention, pressure and sanctions by local authorities, as
well as visibility of good performance in the districts
[23]. Delay in payment from public sector side in the
pilot regions however is still reported. Another initial
challenge was compliance with SOPs at district and
health facility level. This has improved after repeated
training followed by internal coaching and supervision.
A study in Tanzania found that despite supporting
policies, there is limited understanding and recognition
of the PPP concept at district level, coupled with reluc-
tance to engage with non-state actors and mistrust
towards the private sector [24]. Generally, in this specificPPP, the private supplier adhered better to contractual
terms than the public sector districts.
Encouraging metrics, convincing and visible results as
well as positive perceptions of the Jazia PVS in the pilot
regions have facilitated evidence-based policy dialogue.
The challenges of MSD struggling with increasing
demands and procurement difficulties prompted the
Tanzanian government to initiate a national roll-out of
the Jazia PVS as a complementary source of medical
supplies. The required advocacy and initial development
of tools, tendering and establishing a regional PV system
was time-intensive and required substantial lobbying
and dialogue with stakeholders and decision makers.
Enabling factors for the successful implementation of
the pilot included strong political will and support by
the regional secretariat and Health Management Team,
a deep sense of ownership of Jazia PVS by the region
and districts, and an engaged project implementation
team. Constructive collaboration with MSD, TFDA and
health ministries was instrumental for national dialogue.
Particularly facilitating was the sustained leadership by
committed district and regional medical officers. More
practical instruments and drivers were a government
circular to underpin and instruct purchases by health
facilities limited to the two approved suppliers (MSD
and the PV), incorporation of PV operations into the re-
gional management’s routine operations and recognition
of good performance. Participation and engagement of
all actors created ownership and pride in the functional
system. A systemic approach to supply chain manage-
ment including a range of accompanying activities in
pharmaceutical management and accountability was
crucial. These enabling factors were further enhanced by
regular meetings with stakeholders, integration of
pharmaceutical staff in decision-making and operational
research. Dissemination of results and regular policy
dialogue contributed to acceptance and ownership.
Could the significant increase in availability of medi-
cines in the pilot region of Dodoma have happened
without the Jazia PVS? The health system is a highly
complex system with variety of interactions, inter-
dependence of functions, constantly evolving, adapting,
permeable and non-linear in its organisation. The supply
chain itself is a feedback loop and complex structure
with various junctures that affect the final expected out-
come of health commodity availability. Therefore, vari-
ous factors contribute to the success or failure of a
supply chain. Nonetheless, the results of the Jazia PVS
pilot certainly indicate a plausible correlation.
The Prime Vendor model in medical supply chains
is not new. A successful PV system has been imple-
mented for instance under The Pharmaceutical Prime
Vendor Program, a contracting arrangement, through
which the Department of Veterans Affairs in the USA
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outpatients [25].
In Zimbabwe, a vendor system was implemented where
high-cost, slow-moving specialty supplies for hospitals were
ordered and directly delivered from a government-selected
private supplier [26]. In Tanzania, the Mission for Essential
Medical Supplies (MEMS) developed a PV system in 2004
using pooled procurement to purchase from a single
supplier. However the contracted supplier had difficulties
meeting contractual terms, due to underestimating the
complexity of the program, and the PVS failed [17]. An-
other example of a PV is a project funded by the President’s
Emergency Plan for AIDS Relief (PEPFAR) which estab-
lished a “Prime Vendor” in Tanzania, procuring drugs from
approved wholesalers at approved prices. Implementing
partners place orders directly with the PV [17]. This
approach differs from the Jazia PVS in that it does not com-
plement MSD but delivers a separate and uninterrupted
supply of high-quality, affordable products. In contrast, the
Jazia PVS is based on a PPP with fixed prices comparable
to MSD and supplies are funded from health facility own
sources, responding to fiscal decentralization. It therefore
comprises a system and not just a vendor approach. Fur-
ther, Jazia PVS is not a parallel system but anchored within
regional structures based hence assuring sustainability.
Transparency in the procurement procedures has been a
key objective.
The Jazia PVS model can be adapted in health sectors
of other countries. However, the local context will deter-
mine its operational design. The case study in Tanzania
that is described here is specific and embedded in the
larger health system context, responding to locally artic-
ulated needs, available resources, policies and challenges.
Most importantly, a systemic approach is required,
embedding the PVS in a given health system and its
structural, economic and political characteristics.
Scaling up means expansion or replication of an innova-
tive and effective pilot or small-scale projects to reach
more people and broaden the effectiveness of the inter-
vention. Promoting and managing a novel system, dissem-
ination and implementation of innovative and effective
public health interventions, however, present challenges
both for implementers and for the health workforce. Milat
et al. [27] reviewed models and success factors for scaling
up public health interventions. Promoting factors included
among others a robust monitoring and evaluation system,
active engagement of implementers and target population
with participatory approaches, strong leadership and the
use of evidence. Similarly, WHO identifies three fairly
robust generalizations and requirements that promise
success of scaling up of public health interventions [28].
“First, a partnership of organizations working on service
delivery, financing and stewardship (co-ordination, regula-
tion etc.)”.This was achieved in in the pilot region Dodomaby intense and ongoing brainstorming, consultations, par-
ticipatory meetings and policy dialogue at all levels of the
health system. “Second, a highly committed group of indi-
viduals to push it along”. The Jazia PVS project team
together with highly engaged regional actors were able to
implement and provide convincing evidence to support
continuation and expansion of the pilot. Finally, WHO
identifies “monitoring implementation of the scale-up” as
critical for assessing progress relative to overall objectives
and for identifying aspects which are not working well.
Also relevant and recommended is the input of external
experts steering the project and political support at
national level. The main hindering factors have been
documented as financial issues and the amount of admin-
istrative work [29]. Pilot projects tend to be implemented
with a level of input and support that subsequently cannot
be sustained when innovations are taken to scale [30].
The Tanzanian PVS coordination team is well aware
that introducing a model in other quite diverse regions
requires intense and close follow-up and support. Here
the Tanzanian government is called to support, coordin-
ate and monitor and to react to any challenges that may
arise. Transferring successful smaller-scale initiatives
such as this supply chain intervention to other regions
and to a larger scale requires taking differences between
settings into account. Promoting factors include per-
sonal commitment of the local actors and recognizable
benefit for the population. This has been well achieved
in the original pilot regions and now needs to be repli-
cated in all regions of Tanzania. Resistance to change,
particularly to increased transparency and governance in
the supply chain of valuable health commodities is
imminent. Therefore political support at regional level
and experience of project partners is essential.
The government is establishing a centralized Jazia PVS
coordination office to effectively manage, monitor and
backstop the complementary supply system in all 26
regions. Further capacity building and support for the
organizational development is required until the Jazia
PVS is solidly integrated in regional structures and fully
operational in all regions of mainland Tanzania in
collaboration with MSD. The government and related
ministries will need to capitalize on their now expanded
capacity and maintain the technical knowledge gained.
The national roll-out of this successful pilot to
strengthen the public supply chain will face challenges
and risks. For instance, the pilot regions received close
support and monitoring which allowed taking appropri-
ate measures where needed due to external assistance,
favourable regional ownership and strong leadership.
Other regions will receive less close-up support and suc-
cessful implementation will depend on local leadership
and commitment, and support from by the national
coordination office. Accountability continues to be a
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public health supply chain. Auditing and strong support-
ive supervision will be critical.
Since the Jazia PVS is anchored in existing regional and
district structures with a centralized coordination office,
little additional costs will have to be budgeted and
absorbed by regions. Nevertheless, sustainability both in
terms of operational and financial viability, adequate staff
and technical capability will require political commitment.
Conclusions
While MSD will remain the backbone for medicines
supply, Jazia PVS complements MSD efforts and ensures
that health facilities have the medicines and medical
supplies to meet the needs of the people. The PPP
supplements the regular government supply with add-
itional supplies from a single private vendor in a pooled
regional approach. The Jazia PVS is anchored in the
structures of each regional health administration and in
the decentralisation policy of the country. When quality
of health care is improved, the population will be moti-
vated to join the insurance schemes which in turn gener-
ate funds to ensure supply of medicines and provision of
care. It is a new option in that it empowers public health
facilities to purchase supplementary medicines and
supplies with their own resources through a shortened,
standardized and transparent procedure, thus improving
medicine availability without compromising quality or cost.
Scaling of the successful pilot model required solid
evidence of favourable results, strong leadership and
active engagement of stakeholders and implementers, a
systemic approach and highly committed individuals
advocating for change. To ensure sustained momentum
in this endeavour, it will be critical for the government
and related ministries, partners and supply chain actors
to continue leveraging this intervention for a strength-
ened health system. Regional ownership has been instru-
mental and a cornerstone for the success of Jazia PVS in
pilot regions. Similarly, country stewardship of this com-
plementary supply chain will be crucial for sustainable
and effective operations at national level for 26 regions.
Following the nationwide roll-out of Jazia PVS, procure-
ment of complementary medical supplies when MSD is
out of stock now operates within a culture of transparency
and accountability, based on simplified and standardized
procedures in partnership with the private sector.
Endnotes
1The Health Basket is a funding mechanism initiated
in1999 as part of the Government of Tanzania’s decision
to pursue a sector-wide approach (SWAp) in the health
sector. The basket is funded by a number of Development
Agencies that pool un-earmarked resources to support the
implementation of the Health Sector Strategic Plan.2The Community Health Fund (CHF) was established
by the Government of Tanzania with the support of the
World Bank. CHFs are a voluntary community-based
financing scheme in which households pay contributions
to finance part of their basic health care services to
complement the government health financing efforts.
Abbreviations
CHF: Community Health Fund; DP: Development Partners; GPP: Good
Procurement Practice; HPSS: Health Promotion and System Strengthening;
MoF: Ministry of Finance; MoHCDGEC: Ministry of Health, Community
Development, Gender, Elderly and Children; MSD: Medical Stores
Department; PORALG: President’s Office - Regional Administration and Local
Government; PPP: Public-Private Partnership; PPRA: Public Procurement
Regulatory Authority; PV: Prime Vendor; PVS: Prime Vendor system;
RALG: Regional Administration and Local Government; RHMT: Regional
Health Management Team; SDC: Swiss Agency for Development and
Cooperation; SOP: Standard Operating Procedures; TFDA: Tanzania Food and
Drug Authority; TOR: Terms of Reference; TOT: Training of Trainers;
UHC: Universal Health Coverage; WHO: World Health Organization
Acknowledgements
This paper is based on results from the Health Promotion and System
Strengthening Project (HPSS) that is funded by the Swiss Agency for
Development and Cooperation (SDC). The opinions expressed herein are
those of the authors and do not necessarily reflect the views of SDC.
The Health Promotion and System Strengthening (HPSS) project is part of
the development cooperation between Tanzania and Switzerland. It supports
Dodoma, Morogoro and Shinyanga Regions in the areas of health insurance
and pharmaceutical management. In Dodoma, the project supports two
more components on community health promotion and Health Technology
Management. The SDC project is implemented by the Swiss Tropical and Public
Health Institute (Swiss TPH).
We would like to thank the whole HPSS team in Dodoma, Morogoro and
Shinyanga, especially Prof. Victor Meshack who guided the Jazia PVS concept
and Vicky Msamba who supported monitoring. We are grateful to Dr. Ernest
Ibenzi who managed the co-ordination office in Dodoma. We thank all
district pharmacists who contributed to implementation and supported
operations. Very special thanks to Dr. Zainab Chaula, Deputy Permanent
Secretary – Health, PORALG. We acknowledge support by district and
regional health authorities and the HPSS project leader Manfred Stoermer at
SwissTPH. Finally we extend our gratitude to August Kuwawenaruwa for
reviewing and Elisabeth Goffin for proofreading this manuscript.
Funding
Swiss Agency for Development and Cooperation (SDC).
Availability of data and materials
Please contact author for data requests.
Authors’ contributions
KW prepared the concept and coordinated the pilot as technical expert and
lead. RM and WM developed procurement tools and provided advocacy at
regional and national level in collaboration with the HPSS team. JC
supported the initial taskforce and implementation in Dodoma region. KW,
WM, RM, DM, EM and FC drafted SOPs, the M&E framework and training
materials. DM guided implementation in Dodoma region. NK advocated the
PVS at regional and national level and initiated the political decision of
PORALG for national roll-out. EM supported the pilot and coordinated the
national roll-out team. All authors participated in designing the Jazia PVS
package (tools, forms, documents, training materials and communication)
and managed the national roll-out. KW guided the compilation, analysis and
summary of the intervention and drafted the manuscript. All authors contributed,
read and approved the final manuscript.
Ethics approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Wiedenmayer et al. Journal of Pharmaceutical Policy and Practice            (2019) 12:4 Page 10 of 10Competing interests
The authors declare that they have no competing interests.Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Swiss Tropical and Public Health Institute, Basel, Switzerland. 2University of
Basel, Petersplatz 1, 4051 Basel, Switzerland. 3Senior pharmaceutical
consultant, Dar es Salaam and senior lecturer at St. John’s University of
Tanzania, Dodoma, Tanzania. 4Senior pharmaceutical consultant, Dar es
Salaam, Dodoma, Tanzania. 5Health System Resource Center, President’s
Office Regional Administration and Local Government, Dodoma, Tanzania.
6Regional Medical Officer, Regional Administrative Secretary’s Office,
Dodoma, Tanzania. 7Health Promotion and System Strengthening Project,
Dodoma, Tanzania. 8Regional Pharmacist, Regional Administrative Secretary’s
Office, Dodoma, Tanzania. 9Director of Health Services, Social Welfare and
Nutrition Services, President’s Office of Regional Administration and Local
Government, Dodoma, Tanzania.
Received: 17 August 2018 Accepted: 10 January 2019
References
1. Srivastava D, McGuire A. Patient access to health care and medicines across
low-income countries. Soc Sci Med. 2015;133:21–7.
2. Prinja S, Bahuguna P, Tripathy JP, Kumar R. Availability of medicines in
public sector health facilities of two north Indian states. BMC Pharmacol
Toxicol. 2015;16:43.
3. Bigdeli M, Laing R, Tomson G, Babar Z. Medicines and universal health
coverage: challenges and opportunities. J Pharm Policy Pract. 2015;8(1):8.
4. Obare V, Brolan CE, Hill PS. Indicators for universal health coverage: can
Kenya comply with the proposed post-2015 monitoring recommendations?
Int J Equity Health. 2014;13:123.
5. Lu Y, Hernandez P, Abegunde D, Edejer T. Medicine expenditures. In: The
world medicines situation 2011. World Health Organization. 2011 (http://
apps.who.int/medicinedocs/documents/s18767en/s18767en.pdf, Accessed
date 14 Oct 2018.
6. Shayo EH, Senkoro KP, Momburi R, Olsen OE, Byskov J, Makundi EA,
Kamuzora P, Mboera LE. Access and utilisation of healthcare services in rural
Tanzania: a comparison of public and non-public facilities using quality,
equity, and trust dimensions. Glob Public Health. 2016;11(4):407–22.
7. Ushie BA, Ugal DB, Ingwu JA. Overdependence on for-profit pharmacies: a
descriptive survey of user evaluation of medicines availability in public
hospitals in selected Nigerian states. PLoS One. 2016;11(11):e0165707.
8. Shan L, Li Y, Ding D, Wu Q, Liu C, Jiao M, Hao Y, Han Y, Gao L, Hao J, Wang
L, Xu W, Ren J. Patient satisfaction with hospital inpatient care: effects of
trust, medical insurance and perceived quality of care. PLoS One. 2016;
11(10):e0164366.
9. Anselmi L, Lagarde M, Hanson K. Health service availability and health
seeking behaviour in resource poor settings: evidence from Mozambique.
Health Econ Rev. 2015;5:26.
10. Mwabu G, Ainsworth M, Nyamete A. Quality of medical care and
choice of medical treatment in Kenya: an empirical analysis. J Hum
Resour. 1993;28(4):838–62.
11. Kalolo A., Radermacher R, Stoermer M, Meshack M, De Allegri M.
Factors affecting adoption, implementation fidelity, and sustainability of
the redesigned community health Fund in Tanzania: a mixed methods
protocol for process evaluation in the Dodoma region. Glob Health
Action 2015; 8: 10.3402.
12. Agyepong IA, Abankwah DNY, Abroso A, Chun C, Dodoo JNO, Lee S,
Mensah SA, Musah M, Twum A, Oh J, Park J, Yang D, Yoon K, Otoo N,
Asenso-Boadi F. The "Universal" in UHC and Ghana's National Health
Insurance Scheme: policy and implementation challenges and dilemmas of
a lower middle income country. BMC Health Serv Res. 2016;16:504.
13. White J, O’Hanlon B, Chee G, Malangalila E, Kimambo A, Coarasa J, Callahan
S, Levey IR, McKeon K. Tanzania private sector assessment. Bethesda, MD:
strengthening health outcomes through the private sector project, Abt
Associates Inc; 2013.14. Reich M. Public-private partnership for public health. Harvard Center for
Population and Development Studies; 2002.
15. Itika JS, Mashindano O, Kessy F. Success and Constraints for Improving
Public Private Partnership in Health Services Delivery in Tanzania. Dar es
Salaam: The Economic and Social Research Foundation (ESRF); 2011.
16. John Snow, Inc. Getting products to people, How Private Sector Solutions
Can Strengthen Supply Chains for Public Health, Arlington, VA: John Snow,
Inc. 2016.
17. Management Sciences for Health. MDS-3: Managing access to medicines
and health technologies. Arlington: Management Sciences for Health; 2012.
(https://www.msh.org/), Accessed date 14 Oct 2018
18. Printz N, Amenyah J, Serumaga B, Van Wyk D. Tanzania: Strategic review of
the national supply chain for health commodities, SCMS and DELIVER
project; 2013.
19. Deloitte Consulting Ltd. Strategic review of the Medical Stores Department
of Tanzania. The journey to efficiency. Final report. Dar es Salaam: Deloitte
Consulting Limited; 2015.
20. United Republic of Tanzania, Prime Minister’s Office. National public private
partnership (PPP) policy. 2009.
21. United Republic of Tanzania. The Public Procurement Act. 2011.
22. United Republic of Tanzania, Ministry of Health and Social Welfare. Health
Sector Strategic Plan July 2015 – June 2020 (HSSP IV). 2015. Accessed date
14 Jun 2018
23. Kapologwe N, Mori AT, Chilunda F, Meshack M, Kalolo A, Wiedenmayer K.
Reforming supportive supervision of medicines management with an audit
tool in primary health care facilities: a case study of Bahi district. Tanzania
Int J Pharm. 2014;4:108–14. Accessed date 14 Jun 2018
24. Kamugumya D, Olivier J. Health system's barriers hindering implementation
of public-private partnership at the district level: a case study of partnership
for improved reproductive and child health services provision in Tanzania.
BMC Health Serv Res. 2016;16(1):596. Accessed date 14 Jun 2018
25. Gansler J, Lucyshyn W, Harrington L, Cotton Corl A. Prime Vendor
Contracting: Lessons Learned. Center for Public Policy and Private
Enterprise. School of Public Policy, University of Maryland. March 2011.
Accessed date 14 Jun 2018
26. Center for Pharmaceutical Management. Access to essential medicines:
Tanzania, 2001. Prepared for the strategies for enhancing access to
medicines program. Arlington: Management Sciences for Health; 2003.
Accessed date 14 Jun 2018
27. Milat AJ, Bauman A, Redman S. Narrative review of models and success factors
for scaling up public health interventions. Implement Sci. 2015;10:113.
Accessed date 14 Jun 2018
28. World Health Organisation. Scaling up Health Services: Challenges and
Choices. Technical Brief No.3. 2008. Accessed date 14 Jun 2018
29. World Health Organization. Scaling up projects and initiatives for better
health: from concepts to practice. 2016. (http://www.euro.who.int/en/
publications/abstracts/scaling-up-projects-and-initiatives-for-better-health-
from-concepts-to-practice-2016, Accessed date 14 Jun 2018
30. ExpandNet, World Health Organization. Beginning with the end in mind.
Planning pilot projects and other programmatic research for successful scaling
up. Geneva, World Health Organization. 2011. Accessed date 14 Jun 2018
